
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.7399
Open
0.7399
VWAP
0.74
Vol
13.76K
Mkt Cap
4.33M
Low
0.7399
Amount
10.18K
EV/EBITDA(TTM)
--
Total Shares
5.85M
EV
-13.50M
EV/OCF(TTM)
--
P/S(TTM)
--
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Show More
Valuation Metrics
The current forward P/E ratio for Check Cap Ltd (CHEK.O) is -1.07, compared to its 5-year average forward P/E of -3.20. For a more detailed relative valuation and DCF analysis to assess Check Cap Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.20
Current PE
-1.07
Overvalued PE
-0.85
Undervalued PE
-5.56
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2023Q4
YoY :
-3.08%
-4.09M
Operating Profit
FY2023Q4
YoY :
-1.48%
-3.66M
Net Income after Tax
FY2023Q4
YoY :
-0.00%
-0.63
EPS - Diluted
FY2023Q4
YoY :
-16.49%
-3.54M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CHEK News & Events
Events Timeline
2025-06-04 (ET)
2025-06-04
07:07:22
Check-Cap 'publicly condemned' MediPharm Labs, Chairman Chris Taves

2025-05-23 (ET)
2025-05-23
13:04:17
Medipharm Labs provides information on three Apollo Capital nominees

Sign Up For More Events
Sign Up For More Events
News
7.0
06-04NewsfilterCheck-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime
9.0
05-14NewsfilterApollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders
9.0
05-13NewsfilterMediPharm Labs Files Proxy Materials, Issues Chair's Letter to Shareholders
Sign Up For More News
People Also Watch

OTRK
Ontrak Inc
0.290
USD
-5.22%

CTNT
Cheetah Net Supply Chain Service Inc
1.450
USD
0.00%

PAVM
PAVmed Inc
0.576
USD
0.00%

WAFU
Wah Fu Education Group Ltd
1.420
USD
-0.70%

ULY
Urgent.ly Inc
4.830
USD
-0.82%

STRR
Star Equity Holdings Inc
2.030
USD
0.00%

PNBK
Patriot National Bancorp Inc
1.585
USD
+1.60%

RDHL
Redhill Biopharma Ltd
1.191
USD
-9.08%

IPDN
Professional Diversity Network Inc
1.930
USD
0.00%

JCSE
JE Cleantech Holdings Ltd
1.010
USD
0.00%
FAQ

What is Check Cap Ltd (CHEK) stock price today?
The current price of CHEK is 0.7399 USD — it has increased 0 % in the last trading day.

What is Check Cap Ltd (CHEK)'s business?

What is the price predicton of CHEK Stock?

What is Check Cap Ltd (CHEK)'s revenue for the last quarter?

What is Check Cap Ltd (CHEK)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Check Cap Ltd (CHEK)'s fundamentals?

How many employees does Check Cap Ltd (CHEK). have?
